CytoCell P53 (TP53) Deletion FISH Probe (Haematology)

Product summary

Technology FISH
Application Haematology
Areas of interest ALL, AML, CLL, Lymphoma, MDS, MM
Region 17p13.1
17p11.1-q11.1
Label
Product Code LPH 017 (10 tests)
LPH 017-S (5 tests)
Regulatory Status In vitro diagnostic. This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples. Disease information supported by the literature and is not a reflection of the intended purpose of this product.

Documentation

Overview

Probe specification

P53, 17p13.1, Red
D17Z1, 17p11.1-q11.1, Green

The P53 probe mix consists of a 161kb probe, labelled in red that covers the whole P53 (TP53) gene and the flanking regions. The probe mix also contains a control probe for the 17 centromere (D17Z1) that is labelled in green.

Probe information

The TP53 (tumor protein p53) gene at 17p13.1 is a tumour- suppressor gene that has been shown to be deleted in a wide range of human malignancies.

The TP53 gene is one of most important tumour suppressor genes; it acts as a potent transcription factor with fundamental role in the maintenance of genetic stability. Screening for TP53 loss is important as deletions or losses of the short arm of chromosome 17, which includes the TP53 region, are reported in many cancers and are often associated with disease progression, inferior response to treatment and/or a poor prognosis.

In particular, loss of TP53 is reported in 10% of patients with chronic lymphocytic leukaemia (CLL), and is considered to be the poorest prognostic marker in that disease^1,2. In acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), TP53 loss is associated with a poor outcome and is often seen as a marker of disease progression or secondary disease^3-5.

TP53 loss in patients with multiple myeloma is a late event, where is seen as a marker of disease progression and is associated with a very poor prognosis^6,7.

In non-Hodgkin lymphoma, TP53 losses are reported in diffuse large B- cell lymphoma (DLBCL) often as part of ‘dual-hit’ lymphoma or plasmablastic phenotypes⁸. In mantle cell lymphoma (MCL), TP53 losses are associated with a poor outcome, and with a dismal outcome when seen with concurrent CDKN2A deletions⁹.

Fluorescence in situ hybridisation (FISH) microscope image of the CytoCell P53 (TP53) Deletion probe.

What our customers say

I am grateful for the excellent products I receive from CytoCell at a reasonable price, but more importantly the superb customer support. The speed in which I receive answers or suggestions makes my life as a director much easier and allows me to focus on patient care. The quality and consistency of CytoCell’s probes means I can trust the results, and my clients get their results in a timely manner

Dr. Theresa C. Brown

Director, Cytogenetics Laboratory, Hayward Genetics Center, Tulane University School of Medicine

Request a quote
Request a sample

References

Rossi D, et al., Blood. 2013 Feb 21;121(8):1403-12
Baliakas P, et al., Leukemia. 2014;(April):1-8
Grimwade D, et al., Br J Haematol. 2010; (3):17
Seifert H, et al., Leukemia. 2009;23(4):656-63
Stengel A, et al., Blood. 2014;124(2):251-8
Palumbo A, et al., J Clin Oncol. 2015 Sep 10;33(26):2863-9
Fonseca R, et al., Leukemia. 2009 Dec;23(12):2210-21
Simonitsch-Klupp I, et al., Leukemia. 2004 Jan;18(1):146-55
Khayat AS, et al., BMC Gastroenterol. 2009;9:55

Recommended protocol for CytoCell haematology FISH

Select a protocol step to view:

Sample and slide preparation

Spot the cell sample onto a glass microscope slide. Allow to dry.
Immerse the slide in 2x Saline Sodium Citrate (SSC) for 2 minutes at room temperature (RT) without agitation.
Dehydrate in an ethanol series (70%, 85% and 100%), each for 2 minutes at RT.
Allow to dry.